Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Hum Vaccin Immunother. 2021 May 4;17(5):1294-1295. doi: 10.1080/21645515.2020.1824499. Epub 2020 Dec 24.
Osteosarcoma (OS) is the most common malignant bone tumor and often occurs in children. Chemotherapy with methotrexate, cisplatin, doxorubicin, and ifosfamide has greatly improved the prognosis of patients with OS, and most patients have been able to preserve their limbs. However, no progress has been made in the treatment for OS in the past few decades, and the prognosis of patients with metastasis and/or local recurrence remains poor. Therefore, studies aimed at developing new treatment methods for OS are urgently required. Here, we discuss the current status of immunotherapies for OS as well as the current limitations in the field.In recent years, immunotherapy has been shown to be effective for treating several cancers, and its indication is continually increasing. Immunotherapy is also expected to be widely used for treating OS, however, the efficacy of immunotherapy for OS has not been established.
骨肉瘤（OS）是最常见的恶性骨肿瘤，常发生于儿童。甲氨蝶呤、顺铂、多柔比星和异环磷酰胺联合化疗极大地改善了骨肉瘤患者的预后，大多数患者能够保留肢体。然而，在过去几十年中，骨肉瘤的治疗没有取得任何进展，转移和/或局部复发患者的预后仍然很差。因此，迫切需要研究开发治疗骨肉瘤的新方法。在这里，我们讨论了骨肉瘤免疫治疗的现状以及该领域目前存在的局限性。近年来，免疫疗法已被证明对治疗多种癌症有效，其适应证不断增加。免疫疗法也有望广泛用于治疗骨肉瘤，但免疫疗法治疗骨肉瘤的疗效尚未得到证实。
